First Patient Enrolled in Phase 2 Trial for Experimental RRMS Drug
According to a publication from Multiple Sclerosis News Today, German biotechnology company Immunic Therapeutics has successfully enrolled the first participant for its phase 2 clinical trial for experimental relapsing-remitting multiple…